Recently Viewed
Clear AllToday’s Range
52 Week Range
Liquidity
Market cap
$15 Mln
Revenue (TTM)
$1 Mln
Net Profit (TTM)
$0 Mln
ROE
-6.8 %
ROCE
-- %
P/E Ratio
--
P/B Ratio
7.7
Industry P/E
--
EV/EBITDA
-9.7
Div. Yield
0 %
Debt to Equity
0
Book Value
$--
EPS
$-0.1
Face value
--
Shares outstanding
144,300,674
CFO
$-352.89 Mln
EBITDA
$-409.50 Mln
Net Profit
$-465.29 Mln
|
Company
|
YTD
|
1 Month
|
3 Months
|
1 Year
|
3 Years
|
5 Years
|
10 Years
|
|---|---|---|---|---|---|---|---|
|
Applied Therapeutics (APLT)
| 3.0 | 0.3 | -90.1 | -81.7 | -54.5 | -66.9 | -- |
|
BSE Sensex*
| -13.4 | -9.8 | -13.9 | -3.6 | 7.5 | 7.9 | 11.2 |
|
S&P Small-Cap 600#
| -5.8 | -5.3 | -13.7 | -6.3 | 5.3 | 3.0 | 5.5 |
|
Company
|
2025
|
2024
|
2023
|
2022
|
2021
|
2020
|
|---|---|---|---|---|---|---|
|
Applied Therapeutics (APLT)
| -88.3 | -74.2 | 340.8 | -91.5 | -59.3 | -19.3 |
|
S&P Small-Cap 600
| 4.0 | 7.0 | 13.9 | -17.4 | 25.3 | 9.6 |
|
BSE Sensex
| 9.1 | 8.1 | 18.7 | 4.4 | 22.0 | 15.8 |
Is there a threat to the company's solvency?
Can creative accounting be detected through the financial numbers?
How did the company perform in the last one year?
5Y Avg -- 3Y Avg -- TTM --
P/E Ratio
--
--Min --Median --Max
P/B Ratio
--
--Min --Median --Max
Earnings Yield (%)
--
Earnings Yield (%) = EBIT / Enterprise value
PEG Ratio
--
Price = Price / Earnings to growth ratio
Company |
Price ($) | Market Cap ($ Mln) | Revenue (TTM) | Net Profit (TTM) | OPM (%) | ROE (%) | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
|
Applied Therapeutics (APLT)
|
0.1 | 14.9 | 1.0 | -18.1 | -10,073.6 | -- | -- | 7.7 |
| 61.0 | 8,072.9 | 1,091.0 | 202.3 | 31.6 | 31.3 | 36 | 14.2 | |
| 66.7 | 7,755.6 | 88.0 | -785.0 | -808.1 | 197.5 | -- | 60.3 | |
| 43.9 | 11,247.3 | 2,320.1 | 782.6 | 39.0 | 35.5 | 14.9 | 5.0 | |
| 93.8 | 11,306.9 | 982.0 | -416.3 | -42.1 | 348.4 | -- | 55.7 | |
| 64.5 | 7,360.8 | 1,396.6 | 316.9 | 59.8 | 153.6 | 24.3 | 153.4 | |
| 546.9 | 11,592.5 | 958.4 | -288.3 | -27.8 | -42.5 | -- | 16.8 | |
| 498.3 | 13,063.9 | 2,530.2 | 451.1 | 21.3 | 70.2 | 30.1 | 28.0 | |
| 105.4 | 7,603.8 | 0.0 | -425.4 | -- | -36.7 | -- | 6.0 | |
| 310.4 | 7,699.1 | 0.0 | -303.3 | -- | -45.8 | -- | 8.8 |
Applied Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the development of a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need in the United States. The... company's lead product candidate is AT-007 that has completed phase 3 for the treatment of galactosemia in healthy volunteers and adults, in pediatric clinical study for the treatment of galactosemia in kids, for treating enzyme sorbitol dehydrogenase, and for the treatment of phosphomannomutase enzyme-CDG. It develops AT-001 that is in phase 3 clinical trials to treat diabetic cardiomyopathy, as well as for the treatment of diabetic peripheral neuropathy; and AT-003, which is in preclinical studies for the treatment diabetic retinopathy. The company has exclusive license and supply agreement with Mercury Pharma Group Limited to commercialize drug products containing AT-007. Applied Therapeutics, Inc. was incorporated in 2016 and is headquartered in New York, New York. As of February 3, 2026, Applied Therapeutics, Inc. operates as a subsidiary of Cycle Group Holdings Limited. Address: 545 Fifth Avenue, New York, NY, United States, 10017 Read more
Chair of the Board of Directors, Founder, President, CEO & Secretary
Dr. Shoshana Shendelman Ph.D.
Chair of the Board of Directors, Founder, President, CEO & Secretary
Dr. Shoshana Shendelman Ph.D.
Headquarters
New York, NY
Website
Our rating system has guided millions of investors in the past 20 years.
The share price of Applied Therapeutics Inc (APLT) is $0.10 (NASDAQ) as of 04-Feb-2026 09:30 EDT. Applied Therapeutics Inc (APLT) has given a return of -54.45% in the last 3 years.
Since, TTM earnings of Applied Therapeutics Inc (APLT) is negative, P/E ratio is not available.
The P/B ratio of Applied Therapeutics Inc (APLT) is 7.72 times as on 04-Feb-2026, a 94 premium to its peers’ median range of 3.98 times.
PE & PB ratio at the end of financial year.
| Year | P/E Ratio | P/B Ratio |
|---|---|---|
|
2024
|
-1.13
|
2.10
|
|
2023
|
-2.35
|
-16.41
|
|
2022
|
-0.35
|
7.11
|
|
2021
|
-2.22
|
3.72
|
|
2020
|
-5.21
|
5.91
|
The 52-week high and low of Applied Therapeutics Inc (APLT) are Rs 1.50 and Rs 0.09 as of 05-Apr-2026.
Applied Therapeutics Inc (APLT) has a market capitalisation of $ 15 Mln as on 04-Feb-2026. As per SEBI classification, it is a Small Cap company.
Before investing in Applied Therapeutics Inc (APLT), assess your goals, risk tolerance, and if the company aligns with your long-term plan. Carefully review its business model, financials, and valuation. Avoid making decisions based on tips or short-term trends.
New Process Alert 
Seems like you've uploaded a wrong QR code. Please upload the QR code downloaded from MF Central platform.